Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2023-09-22 Earnings Release
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Korekta raportu okresowego za I półrocze 2023 roku - Content (PL)
Earnings Release Classification · 1% confidence The document is a short regulatory announcement (834 characters) from Celon Pharma S.A. stating that there was a technical error ('omyłka') in the previously published 'Śródrocznym skróconym sprawozdaniu finansowym za okres 6 miesięcy zakończony dnia 30 czerwca 2023 roku' (Interim condensed financial statement for the 6 months ended June 30, 2023). Crucially, it states that immediately after publishing this current current report ('niniejszego raportu bieżącego'), the company will make public the corrected periodic report ('skorygowany raport okresowy za I półrocze 2023 roku') and that the corrected tables are presented in the attachment to the current report. This structure—announcing a correction to a previous report and stating the corrected version will follow or is attached—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), as it is not the comprehensive Interim Report (IR) itself, but an announcement *about* the report's status/correction. Given the specific nature of correcting a prior financial filing, RPA is slightly more precise than the general RNS, as it announces the publication/correction of a report. H1 2023
2023-09-22 Polish
Raport niezależnego biegłego rewidenta
Audit Report / Information Classification · 1% confidence The document is explicitly titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Review Report on the Interim Condensed Financial Statements). This document contains the auditor's conclusion based on a review of the financial statements for the period ending June 30, 2023. This fits the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinct from the full Annual Report (10-K) or a simple Earnings Release (ER). The content is a formal review report, not an announcement of a report (RPA) or a general regulatory filing (RNS). H1 2023
2023-09-20 Polish
Raport półroczny
Interim / Quarterly Report Classification · 1% confidence The document is titled 'ŚRÓDROCZNE SKRÓCONE SPRAWOZDANIE FINANSOWE' (Interim Condensed Financial Statement) for the 6-month period ending June 30, 2023. It contains comprehensive financial statements (Statement of Comprehensive Income, Statement of Financial Position, etc.) and a management report (Sprawozdanie Zarządu z działalności). This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2023
2023-09-20 Polish
Podpisanie umowy na realizację i dofinansowanie projektu Celon Pharma S.A. dotyczącego rozwoju klinicznego innowacyjnego inhibitora CPL110 w nowotworach litych FGFR zależnych - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a formal announcement by the Management Board ('Zarząd') of Celon Pharma S.A. regarding the signing of an agreement ('Umowa') with the Medical Research Agency ('Agencja Badań Medycznych') for the co-financing of a commercial project ('Projekt'). It details the total cost (39.8 million PLN), the amount of funding received (19.3 million PLN, 48.4% of costs), the nature of the funding (advance or reimbursement), and the project completion deadline (December 31, 2027). This announcement concerns financing activities, specifically receiving a grant/subsidy for R&D/clinical development. This fits best under 'Capital/Financing Update' (CAP), as it details a significant financial agreement related to capital structure/funding for a project, rather than being a general regulatory filing (RNS) or a management discussion (MDA). Given the document's focus on securing funding for development, CAP is the most appropriate classification.
2023-07-25 Polish
20230725_zawiadomienie_o_zwiekszeniu_udzialu_w_glosach_Celon_Pharma.pdf
Major Shareholding Notification Classification · 1% confidence The document is a formal notification dated 2023-07-25 from Generali Powszechne Towarzystwo Emerytalne S.A. to Celon Pharma S.A. It explicitly references Article 69 of the Polish Public Offering Act ('Ustawa') regarding changes in significant shareholdings. The content details the transfer of assets and the resulting change in the ownership stake (from below 5% to 7.90% / 6.10% of votes) held by Generali OFE following the liquidation of NNLife OFE. This type of mandatory disclosure concerning crossing ownership thresholds (5% threshold mentioned) is classified as a Major Shareholding Notification.
2023-07-25 Polish
Otrzymanie zawiadomienia o zmianie udziału w ogólnej liczbie głosów w Spółce - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document is a short notification (719 characters) from the Management Board of Celon Pharma S.A. regarding receiving a notice from Generali Powszechne Towarzystwo Emerytalne S.A. This notice concerns Generali OFE crossing a threshold of 5% of the total votes in Celon Pharma S.A. due to the liquidation of another fund (NNLife OFE) and the transfer of its assets. The text explicitly states that the full content of the notification is attached ('Pełna treść zawiadomienia stanowi załącznik do niniejszego raportu'). According to the 'MENU VS MEAL' rule, a short announcement stating a report/notification is attached points towards a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this is a specific notification about a change in significant share ownership crossing a threshold, the most appropriate specific category is Major Shareholding Notification (MRQ). However, the document itself is the announcement of receiving the notification, and the actual detailed notification is attached. Given the brevity and the nature of reporting a change in shareholding percentage crossing a threshold, MRQ is the most precise fit for the underlying event, but if the document is merely announcing the receipt of the filing, RPA or RNS might apply. Since the content details the exact new shareholding percentage (6.10% of votes) and the reason, it strongly relates to 'Major Shareholding Notification' (MRQ). I will classify it as MRQ as the core subject matter is the change in major shareholding.
2023-07-25 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.